02487.HK
Cutia Therapeutics
HKSE · Healthcare · Biotechnology · CN
HKD 1.20
−11.76%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 583.0M | 336.2M | 279.6M | 137.6M | 11.4M |
| Cost of Revenue | 279.5M | 140.4M | 136.2M | 66.6M | 3.4M |
| Gross Profit | 303.4M | 195.8M | 143.5M | 71.0M | 7.9M |
| Operating Expenses | |||||
| R&D Expense | 301.9M | 148.7M | 199.0M | 215.7M | 180.8M |
| SG&A Expense | 695.7M | 355.8M | 299.5M | 255.2M | 48.7M |
| General & Admin Expense | 250.8M | 128.9M | 35.8M | 46.9M | 12.7M |
| Selling & Marketing Expense | 435.9M | 218.4M | 263.7M | 208.3M | 35.9M |
| Other Expenses | — | — | 100.1M | 127.1M | 87.6M |
| Total Operating Expenses | 997.6M | 504.4M | 598.6M | 598.0M | 317.1M |
| Cost and Expenses | 1.3B | 644.8M | 734.8M | 677.3M | 320.6M |
| Operating Income (EBIT) | (694.2M) | (308.6M) | (455.1M) | (539.7M) | (309.2M) |
| Non-Operating | |||||
| Interest Income | 14.2M | 6.4M | 11.8M | 23.4M | 17.4M |
| Interest Expense | 12.2M | 9.5M | 10.9M | 4.5M | 1.7M |
| Net Interest Income | (6.3M) | (3.1M) | 951.0K | 18.9M | 15.6M |
| Other Non-Op Income/Expense | (57.0M) | (31.6M) | 21.3M | (1.4B) | (246.6M) |
| Non-Operating Income (excl Interest) | — | — | 6.4M | 1.4B | — |
| EBT (Pre-Tax Income) | (751.2M) | (340.2M) | (433.8M) | (2.0B) | (555.8M) |
| Income Tax Expense | 2.5M | — | — | — | — |
| Bottom Line | |||||
| Net Income | (753.7M) | (340.2M) | (433.8M) | (2.0B) | (555.8M) |
| Earnings from Cont. Ops | (753.7M) | (340.2M) | (433.8M) | (2.0B) | (555.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (753.7M) | (340.2M) | (433.8M) | (2.0B) | (555.8M) |
| Per Share | |||||
| Basic EPS | (HK$2.31) | (HK$1.03) | (HK$1.41) | (HK$9.60) | (HK$6.94) |
| Diluted EPS | (HK$2.31) | (HK$1.03) | (HK$1.41) | (HK$9.60) | (HK$6.94) |
| Revenue Per Share | HK$1.60 | HK$1.02 | HK$0.91 | HK$0.45 | HK$0.14 |
| Shares | |||||
| Basic Shares Outstanding | 363.4M | 330.9M | 307.2M | 305.2M | 80.0M |
| Diluted Shares Outstanding | 363.4M | 330.9M | 307.2M | 305.2M | 80.0M |
| Profitability Metrics | |||||
| EBITDA | (639.3M) | (277.9M) | (430.7M) | (1.9B) | (535.2M) |
| D&A | 58.7M | 30.7M | 30.9M | 42.5M | 18.9M |
| EBIT | (694.2M) | (308.6M) | (461.5M) | (2.0B) | (554.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026